Literature DB >> 1849934

The ability of cultured Langerhans cells to process and present protein antigens is MHC-dependent.

S Aiba1, S I Katz.   

Abstract

There is controversy regarding the ability of short term (2 to 3 days) cultured epidermal Langerhans cells (cLC) to process and present intact protein Ag to primed T cells. Some studies have shown that cLC are potent APC for both haptens and intact protein Ag, whereas in others cLC have been unable to process and present intact protein Ag. In an attempt to resolve this controversy, we tested the ability of Langerhans cells from several strains of mice to process and present intact protein Ag to T cell clones and T cell hybridomas. We found that both cLC and freshly prepared Langerhans cells from various Iak mice, including BALB.k mice, process and present intact protein antigens (i.e., hen egg lysozyme, cytochrome c, and OVA) to T cells. These functions are retained in cLC cultured for 7 days. In contrast, cLC from Iad mice do not process intact protein Ag, such as hen egg lysozyme and myoglobin, although they can present relevant peptides to specific T cells and are potent stimulators of allogeneic responses. Furthermore, cLC from (Iak x Iad)F1 mice process and present intact protein Ag to Iak-restricted T cells, but not to Iad-restricted T cells. Although cLC that processed and presented intact protein Ag to T cells exhibited enhanced class II MHC expression, they were, on a per cell basis, somewhat less efficient than were fresh Langerhans cells. Finally, we found that if Iad Langerhans cells are pulsed with intact protein Ag and then cultured for 3 days, they are then fully capable of inducing Ag- and MHC-specific T cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849934

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Endocytosis by antigen presenting cells: dendritic cells are as endocytically active as other antigen presenting cells.

Authors:  T P Levine; B M Chain
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

Review 2.  The immunologic properties of epidermal Langerhans cells as a part of the dendritic cell system.

Authors:  N Romani; G Schuler
Journal:  Springer Semin Immunopathol       Date:  1992

3.  Cultured human Langerhans' cells are superior to fresh cells at presenting native HIV-1 protein antigens to specific CD4+ T-cell lines.

Authors:  G Girolomoni; M T Valle; V Zacchi; M G Costa; A Giannetti; F Manca
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

4.  Flow cytometric analysis of cytokine receptors on human Langerhans' cells. Changes observed after short-term culture.

Authors:  A Larregina; A Morelli; E Kolkowski; L Fainboim
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

5.  Internalization of surface HLA-DR molecules by human epidermal Langerhans cells: analysis by flow cytometry and confocal microscopy.

Authors:  H Rizova; P Carayon; L Michel; A Barbier; F Lacheretz; L Dubertret
Journal:  Cell Biol Toxicol       Date:  1994-12       Impact factor: 6.691

Review 6.  Contact dermatitis. Clinical perspectives and basic mechanisms.

Authors:  A Nasir; A A Gaspari
Journal:  Clin Rev Allergy Immunol       Date:  1996       Impact factor: 8.667

Review 7.  Cutaneous defenses against dermatophytes and yeasts.

Authors:  D K Wagner; P G Sohnle
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

8.  Murine epidermal Langerhans cells express CD48, which is a counter-receptor for mouse CD2.

Authors:  H Ozawa; S Aiba; S Nakagawa; H Tagami
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

9.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.